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The transcriptional regulator ZNF398 mediates
pluripotency and epithelial character downstream
of TGF-beta in human PSCs
Irene Zorzan 1,8, Marco Pellegrini 1,5,8, Mattia Arboit1, Danny Incarnato2,3,6, Mara Maldotti2,3,
Mattia Forcato4, Guidantonio Malagoli Tagliazucchi4,7, Elena Carbognin 1, Marco Montagner 1,
Salvatore Oliviero 2,3✉ & Graziano Martello 1✉
Human pluripotent stem cells (hPSCs) have the capacity to give rise to all differentiated cells
of the adult. TGF-beta is used routinely for expansion of conventional hPSCs as flat epithelial
colonies expressing the transcription factors POU5F1/OCT4, NANOG, SOX2. Here we report
a global analysis of the transcriptional programme controlled by TGF-beta followed by an
unbiased gain-of-function screening in multiple hPSC lines to identify factors mediating TGF-
beta activity. We identify a quartet of transcriptional regulators promoting hPSC self-renewal
including ZNF398, a human-specific mediator of pluripotency and epithelial character in
hPSCs. Mechanistically, ZNF398 binds active promoters and enhancers together with
SMAD3 and the histone acetyltransferase EP300, enabling transcription of TGF-beta targets.
In the context of somatic cell reprogramming, inhibition of ZNF398 abolishes activation of
pluripotency and epithelial genes and colony formation. Our findings have clear implications
for the generation of bona fide hPSCs for regenerative medicine.
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Human pluripotent stem cells (hPSCs) have been derivedfrom human blastocysts as human embryonic stem cells(hESCs1) or from somatic cells via transcription factor-
mediated reprogramming as induced pluripotent stem cells
(hiPSCs2,3). Initially hPSCs were cultured on layers of inactivated
fibroblasts (feeder cells), which produce several adhesion and
signalling molecules. Alternatively, the medium was conditioned,
or enriched by unknown secreted factors, by fibroblasts before
their use with hPSCs. Such poorly defined culture systems
represented a hurdle to the identification of key signals regulating
pluripotency. Importantly, chemically defined conditions for the
expansion of hPSCs have been reported4–7. Despite variations in
the media composition, ligands of the TGF-beta family are
invariably added or produced by feeder cells8,9. Indeed, TGF-beta
signalling has been shown to be critical for the maintenance of
pluripotency in hPSCs10,11. However, the mechanisms of action
of the TGF-beta signal remain poorly characterised.
TGF-beta ligands such as TGF-beta1/2/3 (TGFB1/2/3), Nodal and
Activin A bind a dimer of type II serine/threonine kinase receptors,
which in turn phosphorylate and activate two type I receptors,
leading to the formation of a hetero-tetrameric receptor complex.
Activation of the receptor complex leads to phosphorylation of
SMAD2 and SMAD3, the receptor-SMADs (R-SMADs). Phos-
phorylated R-SMADs form heteromeric complexes with SMAD4
and translocate into the nucleus, where they bind target genes.
SMAD3 binds the DNA directly, while SMAD2 needs SMAD4 to
do so12–14, in combination with the histone acetyltransferase
EP300, ultimately leading to activation of target genes. R-SMADs
are known to interact with additional transcription factors that may
vary between different cell types15, resulting in activation of cell
type-specific transcriptional programmes (see Supplementary
Fig. 1a for a diagram of the TGF-beta pathway)12,13. In order to
understand how TGF-beta signalling regulates the behaviour of
hPSCs, it is critical to identify genes directly induced by R-SMADs.
Core pluripotency factors—POU5F1/OCT4, NANOG, SOX2—
were initially identified in murine naïve pluripotent cells16–18 and
were then found to be functionally relevant in hPSCs19. A large
set of additional murine pluripotency factors have been identi-
fied20, the majority of which are not expressed in conventional
human PSCs, potentially because of differences between species
or because conventional hPSCs are in a more advanced devel-
opmental state called primed pluripotency. Although naïve hPSCs
have been recently generated either directly from embryos or by
reprogramming of somatic cells21–24, they are not the focus of
this study and, for clarity, we should stress that the acronyms
hPSCs, hESCs and hiPSCs indicate only human conventional
pluripotent cells in a primed state.
Here, we study conventional hPSCs with the aim of isolating
human-specific pluripotency regulators that could reveal differ-
ences between PSCs of different species, or could play a critical
role for induction of human pluripotency.
In this study, we characterise the transcriptional programme
activated by TGF-beta/SMAD3 signalling in hPSCs. We identify
several potential downstream mediators and test them using a gain-
of-function approach. TGF-beta appears to maintain pluripotency
via induction of four factors. Among them, we extensively char-
acterise a transcriptional regulator, called ZNF398, which induces
genes associated with pluripotency and epithelial character in col-
laboration with SMAD3 and the histone acetyltransferase EP300.
Moreover, ZNF398 knockdown during somatic cell reprogramming
causes a drastic reduction in iPSC colonies.
Results
Identification of TGF-beta transcriptional targets in hPSCs.
We expanded hPSCs under chemically defined conditions4,5 and
validated the known role of TGF-beta in maintenance of plur-
ipotency using SB431542 (SB43), an inhibitor of TGFBR1 and
ACVR1B/C, the type I receptors mediating TGFB1/2/3, Activin
and Nodal signalling (Supplementary Fig. 1a). SB43 reduced
phosphorylation of SMAD3 downstream of TGFB1 and reduced
the levels of the pluripotency factors POU5F1/OCT4, PRDM14
and NANOG (Fig. 1a and Supplementary Fig. 1b) as previously
reported5–7.
Human pluripotent colonies are composed of a monolayer of
cells expressing epithelial markers. SB43 treatment induces also a
morphological change, with loss of cell–cell contact, reduction of
epithelial markers and upregulation of mesenchymal markers
(Fig. 1b and Supplementary Fig. 1c), as previously described25.
We decided to study how TGF-beta controls gene programmes
associated with pluripotency and the epithelial character with an
unbiased functional approach based on the identification of direct
transcriptional targets followed by functional validation26,27. We
reasoned that TGF-beta transcriptional targets should be bound
by SMAD2/3 and either downregulated upon signal inhibition or
rapidly induced upon stimulation. SMAD2 and SMAD3 can also
form heterodimers14 and have redundant functions in pluripotent
cells28. We focused on SMAD3, given that it is more abundant
than SMAD2 in hPSCs and it binds directly to the DNA12,13
(Supplementary Fig. 1d). We intersected SMAD3 chromatin
immunoprecipitation followed by high-throughput sequencing
(ChIP-seq) with gene expression data from cells treated with
SB43 and identified 195 genes downregulated and bound by
SMAD3 (Fig. 1c and d, top panel yellow dots on the left).
Moreover, by intersecting SMAD3-bound genes with genes
induced after 4 h of acute stimulation, we identified 61 additional
putative targets and 20 that were also among the downregulated
genes (Fig. 1c and d, bottom panel yellow dots on the right).
Several known TGF-beta direct targets, such as LEFTY1/2, SKIL
and SMAD7, were identified (Fig. 1d), supporting the validity of
our approach.
We then refined our gene list by focusing on genes encoding
for transcriptional regulators, such as transcription factors or
chromatin modifiers, given that such classes of proteins have the
capacity to direct transcriptional programmes. Finally, we
included only genes robustly expressed (>3 RPKM in hPSCs)
(Supplementary Fig. 1e), obtaining a list of 21 candidates (for all
datasets, see Supplementary Data 1).
We performed qPCR to independently validate our putative
TGF-beta targets. In particular, we tested the responsiveness to both
TGFB1 and Activin A, two ligands commonly used for hPSCs
expansion4–7 (Supplementary Fig. 1a and f). We also tested whether
targets were responsive to the TGF-beta signal when cells were
expanded either on feeders or under feeder-free conditions, given
that the TGF-beta signal is active and maintains pluripotency under
both conditions (Supplementary Fig. 1g)5,8,9. After extensive
validation, we identified eight genes (ID1, MYC, BCOR, KLF7,
OTX2, ZNF398, NANOG and ETS2) as bona fide TGF-beta and
Activin A transcriptional targets in hPSCs (Fig. 2a, b).
Functional identification of pluripotency regulators. If a gene is
a critical downstream mediator of the TGF-beta signal in hPSCs,
its forced expression should maintain pluripotency also when
TGF-beta signalling is inhibited. To test this hypothesis, we stably
expressed our candidates in hiPSCs and hESCs using piggyBac
(PB) vectors.
First, we performed a clonal assay, which allows us to quantify
the fraction of hPSCs able to self-renew, giving rise to pluripotent
colonies. Cells transfected with an empty vector formed a reduced
number of alkaline phosphatase (AP)-positive pluripotent
colonies when treated with SB43 (Fig. 3a and Supplementary
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Fig. 2a). Only expression of NANOG, KLF7, MYC and ZNF398
resulted in full rescue in formation of AP-positive colonies in the
presence of SB43, while other factors had only a partial, or no
effect. Second, under forced expression of either NANOG, KLF7,
MYC or ZNF398 the cells maintained a flat epithelial-like
morphology, generally associated with pluripotency (Fig. 3b),
upon SB43 treatment, while other factors failed to do so. Third,
NANOG, KLF7, MYC and ZNF398 were each able to maintain
expression of pluripotency markers (Fig. 3c) in presence of SB43,
although they displayed specificity for different targets. For
instance, ZNF398 and NANOG activated robustly PRDM14
expression. Quantitative immunostaining confirmed maintenance
of OCT4 and NANOG at the protein levels (Fig. 4a). Comparable
results were also obtained after prolonged culture with SB43
(Supplementary Fig. 2b–d). We confirmed our results in an
additional hESC line (Supplementary Fig. 3a–c) and confirmed a
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Fig. 1 Identification of TGF-beta/SMAD3 transcriptional targets in hPSCs. a Left: Morphology of KiPS treated with SB43 (10 µM) or the vehicle DMSO
for 5 days. Right: Immunostaining for phosphorylated SMAD3 (pSMAD3) and the pluripotency markers NANOG and POU5F1/OCT4 shows a reduction of
these markers after 5 days of SB43 treatment. See also Supplementary Fig. 1c for additional markers. Representative images of four independent
experiments for NANOG and POU5F1/OCT4 and two independent experiments for pSMAD3 are shown. Scale bars 50 µm. b Gene-expression analysis by
qPCR of KiPS treated with SB43 or DMSO for 5 days. Bars indicate the mean ± SEM (standard error of the mean) of four independent experiments shown
as dots. Expression was normalised to the mean of DMSO samples. Unpaired two-tailed Mann–Whitney U test. Source data are provided as a Source Data
file. c Approach used to identify potential SMAD3 direct targets. See also Supplementary Fig. 1e. d Top: Transcriptome analysis of hESCs treated with SB43
for 48 h (microarray data from ref. 10). Dark grey dots indicate differentially expressed genes (DEGs) for −1 > Log2 fold-change > 1 and p-value < 0.05.
Orange dots refer to DEGs bound by SMAD3 (data from ref. 15), max distance between peak midpoint and TSS: ±50 kb. p-values were calculated with
limma (v3.18.13)64 and were adjusted for multiple testing with Benjamini–Hochberg correction. Bottom: Transcriptome analysis of hiPSCs treated for 4 h
with mTeSR after 16 h of SB43 treatment (RNA-seq data, in this study). Dark grey dots indicate DEGs for −0.585 > Log2 fold-change > 0.585
(corresponding to an increase of 50%) and p-value < 0.05. Orange dots refer to DEGs bound by SMAD3. Known SMAD3 targets, such as NANOG,
LEFTY2, SKIL and SMAD7 serve as positive controls10,11,13. p-values were calculated with edgeR package (v3.4.2)60 and were adjusted for multiple testing
with Benjamini–Hochberg correction.
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similar level of transgene expression in different cell lines for
different constructs (Supplementary Fig. 3d).
Taken together these results indicate that forced expression of
NANOG, KLF7, MYC and ZNF398 is individually sufficient to
stably maintain an ESC-like state upon TGF-beta inhibition. Thus,
we identified from the literature an extended suite of functional
regulators of human pluripotency: FOXO129, PRDM1430, BCOR31,
LIN28A3, LIN28B32, DPPA2/433, SOX219, UTF134 and, in the
present work, we identified the transcription factors KLF7 and
ZNF398.
We noticed that MYC had a strong effect on AP-positive colony
formation and morphology despite the partial effects on OCT4 and
NANOG expression (Figs. 3a, b and 4a), suggesting that MYC
might maintain pluripotency via other pluripotency factors. We
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Fig. 2 Validation of TGF-beta transcriptional targets. a Balloon plot summarising validation experiments. Balloon size indicates the statistical significance,
colour indicates the fold-change in expression relative to DMSO-treated hPSCs. Left: Microarray data as in top panel of Fig. 1d were independently
validated by qPCR. Validation experiments were performed in two different culture conditions: feeder-free or on feeders (MEF). Expression was normalised
to the mean of DMSO-treated cells. Right: RNA-seq data as in bottom panel of Fig. 1d were independently validated by qPCR. Expression was normalised to
the mean of SB43-treated samples. The grey box highlights the known direct targets of SMAD3 (positive controls, including SKIL, one of the 21 candidates).
Transcriptional SMAD3 targets independently confirmed are highlighted in bold. For qPCR validation, five independent experiments were performed for
each condition. Unpaired two-tailed t-test, p-values were not adjusted. See also Supplementary Fig. 1f, g. Source data are provided as a Source Data file.
b Example of SMAD3 binding and gene expression analysis of three validated targets. Top: Gene tracks represent binding of SMAD3 (data from ref. 15) at
the indicated gene loci. Red lines indicate the regions validated by ChIP-qPCR. Center: ChIP-qPCR on SMAD7, NANOG and ZNF398 loci was performed
using anti-SMAD3 and anti-SMAD2 or a rabbit control IgG antibody in BG01V (dark grey) and H9 (light grey) cell lines. Enrichment is expressed as a
percentage of the DNA inputs. Bars indicate the mean of two biological replicates shown as dots. Bottom: Gene expression analysis by qPCR. Bars indicate
mean ± SEM of n= 7, 7, 5, 7, 9, 10, 8, 6 biological replicates over six independent experiments shown as dots for SMAD7, n= 7, 6, 5, 6, 5, 5, 5, 5 biological
replicates over five independent experiments shown as dots for NANOG, and n= 8, 7, 5, 6, 9, 10, 8, 6 biological replicates over six independent
experiments shown as dots for ZNF398. Expression was normalised to the mean of SB43 16 h samples. Unpaired two-tailed t-test. Source data are provided
as a Source Data file.
a
c
b
Fig. 3 Functional identification of pluripotency regulators in hPSCs. a Left: Clonal assay quantification of hESCs (HES2, red bars) and hiPSCs (KiPS,
orange bars) stably expressing an empty vector control (Empty) or eight different SMAD3 targets identified in Fig. 2a. Two thousand cells were seeded at
clonal density in the presence of DMSO or SB43 and stained for alkaline phosphatase (AP) after 5 days. Bars show the mean ± SEM percentage of AP-
positive colonies. Dots represent independent experiments (n= 7, 10 for Empty DMSO; n= 7, 10 for Empty SB43; n= 3, 4 for NANOG SB43; n= 2, 2 for
KLF7 SB43; n= 4, 3 for MYC SB43; n= 3, 2 for ZNF398 SB43; n= 3, 3 for ID1 SB43; n= 2, 1 for BCOR SB43; n= 3, 2 for ETS2 SB43; n= 3, 1 for OTX2 SB43
in HES2 and KiPS, respectively). Unpaired two-tailed Mann–Whitney U test relative to Empty SB43 samples. Right: Representative images of clonal assay
performed in KiPS. See also Supplementary Fig. 3a for results obtained in H9 hESCs. Scale bars 500 µm. Source data are provided as a Source Data file.
b Morphology of HES2 colonies stably expressing an empty vector (Empty) in presence of DMSO or SB43 and HES2 stably expressing the eight SMAD3
targets in presence of SB43. Representative images of three independent experiments are shown. See also Supplementary Fig. 3b for results obtained in
H9. Scale bars 200 µm. c Gene expression analysis by qPCR of HES2 (light green bars) and KiPS (dark green bars) stably expressing an Empty vector or the
eight SMAD3 targets and treated with or without SB43 for 5 days. Bars indicate mean ± SEM of independent experiments, shown as dots (n= 5, 5 for
NANOG overexpression; n= 2, 2 for KLF7 overexpression; n= 4, 4 for MYC overexpression; n= 4, 4 for ZNF398 overexpression, n= 2, 4 for ID1
overexpression; n= 2, 2 for BCOR overexpression; n= 2, 1 for ETS2 overexpression; n= 1, 2 for OTX2 overexpression in HES2 and KiPS, respectively).
Expression was normalised to the Empty DMSO samples. Unpaired two-tailed Mann–Whitney U test. Source data are provided as a Source Data file.
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performed transcriptome analysis and observed that MYC robustly
activated UTF1, KLF7, LIN28B and DPPA2, despite the mild effect
on NANOG and OCT4 (Fig. 4b). Similarly, NANOG, KLF7 and
ZNF398 activated completely distinct sets of pluripotency regula-
tors. We further extended our analysis to all genes highly expressed
in hPSCs that were significantly reduced upon SB43 treatment for
5 days. We identified 538 genes downregulated, as a proxy for genes
generally associated with human pluripotency (Fig. 5a, mean fold-
reduction relative to Empty-DMSO and Empty-SB43= 3.75×),
among them were also PRDM14 and NANOG. All of our four
factors under study were able to rescue such global transcriptional
effect (Fig. 4c, see data in Supplementary Data 2).
Murine epiblast stem cells (EpiSCs) are primed pluripotent
cells derived from the post-implantation epiblast35,36. EpiSCs
share several molecular features with primed hPSCs37, including
the requirement of TGF-beta for self-renewal10. Therefore, we
asked whether forced expression of the four factors would
maintain pluripotency also in EpiSCs. We generated both
GOF1827 and OEC238 EpiSCs stably expressing the four
transcription factors (Supplementary Fig. 4a). TGF-beta inhibi-
tion led to a reduction of Nanog, Oct4, Otx2 and Fgf5
(Supplementary Fig. 4b) and none of the four factors were able
to maintain the expression of the markers analysed, with the
exception of Otx2 maintained only by KLF7. We conclude that
the ability of NANOG, KLF7, MYC and ZNF398 to maintain
pluripotency is not conserved in murine EpiSCs.
In sum, our results indicate that in hPSCs, TGF-beta
maintains pluripotency mainly via a quartet of transcriptional
regulators, each one preferentially activating a specific subset of
pluripotency factors. Among these, NANOG and MYC have
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Fig. 4 A quartet of transcriptional regulators maintain pluripotency. a Left: immunostaining for the pluripotency markers NANOG and POU5F1/OCT4 of
KiPS stably expressing an empty vector control (Empty) in presence of DMSO or SB43 and KiPS stably expressing NANOG, KLF7, MYC or ZNF398 in
presence of SB43 for 5 days. Representative images of three independent experiments are shown. Right: Violin plots showing fluorescence intensity
quantification of NANOG and OCT4. For each condition, at least 1200 nuclei from five randomly selected fields were analysed. Box plot indicates 25th,
50th and 75th percentile; whiskers indicate minimum and maximum. Scale bars 20 µm. See also Supplementary Fig. 3c for results obtained in H9. Source
data are provided as a Source Data file. b Diagrams showing an extended set of pluripotency regulators. Gene expression analysis by RNA-seq of KiPS
stably expressing an empty vector, NANOG, KLF7, MYC or ZNF398 and treated with SB43 for 5 days. Colours indicate the fold-change relative to Empty
DMSO sample, thus yellow indicates the endogenous expression of a given gene in undifferentiated hPSCs. c Box plot showing absolute expression levels
(normalised counts, TPM) of 538 genes DOWN-regulated by SB43 treatment (5 days) in KiPS stably expressing an empty vector (see Fig. 5a, blue dots).
Shown data refers to KiPS transfected with the empty vector in the presence of DMSO or SB43 (n= 4, 4 independent experiments, respectively) and for
KiPS stably expressing NANOG, KLF7, MYC or ZNF398 in presence of SB43 for 5 days (n= 2, 2, 2, 2 independent experiments, respectively). Average
fold-change relative to Empty SB43 sample (X) is reported for each condition. Box plots indicate 25th, 50th and 75th percentile; whiskers indicate
minimum and maximum. Unpaired two-tailed t-test.
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been extensively investigated as pluripotency regulators10,11,19,39;
KLF7 is a Kruppel-like factor and other members of the same
family, such as KLF2/4/5, are known regulators of pluripo-
tency40. Conversely, ZNF398 has never been implicated in
regulation of pluripotency, prompting us to choose it for further
molecular characterisation.
ZNF398 represses differentiation and mesenchymal genes.
When TGF-beta is blocked hPSCs lose pluripotency and undergo
a morphological change. After focusing on the pluripotency
regulators (Figs. 3 and 4), we decided to study the global effect of
TGF-beta on hPSC function. Thus, we performed an unbiased
transcriptional analysis and observed that upon SB43 treatment
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538 genes were downregulated and 717 were upregulated
(Fig. 5a). Gene Ontology (GO) enrichment analysis identified
several categories associated with cell adhesion, epithelial to
mesenchymal transition and organisation of the extracellular
matrix, in agreement with the observed morphological change
(Fig. 5b). Among them we identified a subset of genes specifically
associated with epithelial character, that were downregulated by
SB43 (Fig. 5c, epithelial). Moreover, we observed several gene
categories associated with formation and function of neural cells
(Fig. 5b), corresponding to a set of genes upregulated by SB43
(Fig. 5c, neuroectodermal). Upregulation of neuroectodermal
genes was expected from studies performed in different model
systems showing that TGF-beta, Activin A and Nodal block
neuroectoderm formation41,42. Indeed, inhibition of TGF-beta is
commonly used for neuroectodermal differentiation protocols43.
Next, we asked whether the forced expression of ZNF398 was
able to counteract such transcriptional changes and observed a
reduction in neuroectodermal genes and boosted expression of
epithelial genes (Fig. 5c). We conclude that ZNF398 is activated
by TGF-beta to maintain the correct expression of neuroecto-
dermal and epithelial genes in hPSCs.
Next, we asked whether ZNF398 would be required to control
TGF-beta-dependent transcriptional programmes. We performed
siRNA-mediated knockdown of ZNF398 and observed no effect
on self-renewal (Supplementary Fig. 5a, b), as expected from the
presence of four factors that are individually able to maintain
pluripotency downstream of TGF-beta. However, ZNF398
knockdown during the early phases (5 days) of differentiation
resulted in further reduction of pluripotency and epithelial
markers, and enhanced induction of neuroectodermal genes
(Fig. 5d, see also Supplementary Fig. 5c) to an extent comparable
or greater than NANOG knockdown.
To further investigate the capacity of ZNF398 to regulate
pluripotency and the epithelial character of hPSCs in an
independent assay, we performed embryoid bodies (EBs) differ-
entiation. Forced expression of ZNF398 was able to activate
expression of pluripotency and epithelial markers, while repressing
mesenchymal and germ layer markers relative to control cells
(Fig. 5e). Collectively, these results indicate that ZNF398 promotes
the expression of pluripotency and epithelial markers and represses
genes associated with differentiation of hPSCs.
ZNF398 activates transcription in concert with SMAD3. We
next sought to understand the molecular mechanism by which
ZNF398 promotes pluripotency and epithelial character. ZNF398
contains several zinc-finger domains and it has been shown to
recognise specific DNA sequences in COS-1 cells44. Therefore, we
performed ChIP-seq for ZNF398 in two different hESCs lines and
identified genomic regions bound by it containing a DNA motif
similar to other ZNF factors (Supplementary Fig. 6a). Cooperative
binding among transcription factors has been reported in several
stem cell systems, thus we asked how similar the genome-wide-
binding profile of ZNF398 is to those of other transcriptional
regulators (data from CODEX45). Surprisingly, we found that
ZNF398 clustered more closely with SMAD3 and the histone
acetyl-transferase EP300, compared to the core pluripotency fac-
tors OCT4/NANOG or the Polycomb components (Fig. 6a, top
panel). A similar analysis conducted on histone modifications-
associated ZNF398 with regions decorated by acetylation of his-
tone 3 on lysine 9 or 27 (Fig. 6a, bottom panel). Clustering results
are confirmed by strong colocalisation of ZNF398, SMAD3, EP300
and H3K27ac (Fig. 6b). Histone acetylation is associated with both
active promoters and enhancers, so we looked at the distribution
of mono-methylation and tri-methylation of histone 3 on lysine 4,
associated with active enhancers and promoters, respectively. We
looked at ZNF398 peaks and found that 3595 ZNF398 peaks out
of 5771 appeared as active enhancers (high levels of H3K4me1 and
low H3K4me3), while the remaining 2176 peaks as active pro-
moters (high H3K4me3). We conclude that ZNF398 preferentially
colocalises with SMAD3 and EP300 at active enhancers and
promoters in hPSCs.
The frequent colocalisation may be due to binding to
neighbouring DNA regions or to physical interaction. A co-
immunoprecipitation (Co-IP) assay indicates that SMAD3 and
ZNF398 form a complex in hPSCs (Fig. 6c).
We observed that ZNF398 bound and activated the pluripo-
tency factor LIN28B and the epithelial master regulator epithelial
splicing regulatory protein 1 (ESRP146) (Fig. 7a), matching the
pro-pluripotency and pro-epithelial activity of ZNF398. Interest-
ingly, we also observed that LEFTY1, a known TGF-beta direct
target, was also co-bound by ZNF398 (Fig. 7a). We therefore
hypothesised that ZNF398 might potentiate the transcription of
TGF-beta targets by binding SMAD3 targets. We functionally
tested this hypothesis by comparing hPSCs expressing ZNF398
against control hPSCs. ZNF398 boosted the basal expression of
LEFTY1 by >10 fold (i.e. in the presence of TGF-beta), and was
even able to maintain residual LEFTY1 expression in the absence
of TGF-beta signalling (Fig. 7b). We extended our analysis to all
SMAD3 direct target genes (Fig. 1c) and observed that 23 out of
81 were also co-bound by ZNF398 (Fig. 7c, enrichment of 3.67
fold over those expected by chance, p-value= 3.49e−12, Chi-
squared test). Importantly, the entire set of SMAD3-ZNF398 co-
bound genes were significantly upregulated in cells expressing
ZNF398 (Fig. 7d), further indicating a functional role of ZNF398
as activator of SMAD3 co-bound targets. This activity is specific
Fig. 5 ZNF398 represses differentiation and mesenchymal genes. a Transcriptome analysis of KiPS stably expressing an empty vector and treated with
SB43 for 5 days. DOWN-regulated (Log2 fold-change <−1 and p-value < 0.01) and UP-regulated (Log2 fold-change > 1 and p-value < 0.01) genes are
indicated in blue and orange, respectively. Known TGF-beta targets (LEFTY1, LEFTY2) serve as controls. Not adjusted p-values were calculated with Wald
Test. b GO term analysis for biological processes of DOWN-regulated genes (left, blue bars) and UP-regulated genes (right, orange bars) revealed a
statistically significant enrichment (p-value < 0.05) for genes involved in cell adhesion, epithelial to mesenchymal transition, organisation of extracellular
matrix (highlighted in red) and neural development (highlighted in green). p-values were calculated by Fisher Exact test using DAVID database63.
c Heatmap for markers of neuroectodermal and epithelial character. RNA-seq data derived from KiPS stably expressing an empty vector (Empty) or
ZNF398 and treated with DMSO or SB43 for 5 days. Z-scores of row-scaled expression values (TPM) are shown. Orange and blue indicate high and low
expression, respectively. Markers of epithelial (EPCAM, ESRP1, EZR) and neuroectodermal identity (SIX3, ENC1, PAX3) are highlighted. d Gene expression
analysis by qPCR of H9 transfected with the indicated siRNAs (a non-targeting siRNA (siCONTROL) or a pool of two validated siRNAs (siNANOG and
siZNF398)) and treated with or without SB43 for 5 days. See also “Methods” section. Bars indicate the mean of two independent experiments shown as
dots. Expression was normalised to the mean of siCONTROL treated with SB43 samples. See also Supplementary Fig. 5 for siRNA validation and for
additional markers. Source data are provided as a Source Data file. e Gene expression analysis by qPCR of EBs differentiation of KiPS stably expressing an
empty vector (Empty, light orange) or ZNF398 (dark orange) analysed at three different time points (Day 0, Day 5 and Day 15) of differentiation. Bars
indicate the mean ± SEM of five independent experiments, shown as dots. Expression was normalised to the mean of Empty Day 0 sample. Unpaired two-
tailed Mann–Whitney U test. Source data are provided as a Source Data file.
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for ZNF398, given that NANOG expression had no discernible
effect on SMAD3-ZNF398 targets. Among the genes upregulated
in hPSCs expressing ZNF398, we observed strong induction of
several established direct targets of TGF-beta signal, such as
LEFTY1/2, CER1, TGFB1 and NODAL (Fig. 7e). We also analysed
the dynamics of R-SMADs nuclear entry upon TGF-beta
stimulation. Sixty minutes of treatment were sufficient to induce
phosphorylation of SMAD3 and translocation from the cyto-
plasm to the nucleus (Supplementary Fig. 6b–d). Ectopic ZNF398
expression led to accelerated and enhanced nuclear translocation.
In sum, we conclude that ZNF398 colocalises with SMAD3 at
active enhancers and promoters, activating the transcription of
TGF-beta targets in hPSCs.
ZNF398 could be either a hPSC-specific or a general activator of
the TGF-beta signal. We identified only two human cell lines
expressing ZNF398 comparably to hPSCs (Supplementary Fig. 7a)
and performed ZNF398 downregulation or over-expression,
observing no differences in the induction of TGF-beta direct targets
(Supplementary Fig. 7b, c). In two EpiSCs lines, stable expression of
Zfp398—the ZNF398mouse orthologue—we also observed no effect
on the levels of TGF-beta targets (Supplementary Fig. 7d), in stark
contrast with what we observed in hPSCs expressing ZNF398. We
conclude that, among all the cell types we tested, ZNF398 activates
the TGF-beta signal only in hPSCs.
ZNF398 is required for somatic cell reprogramming. So far, our
results indicate that ZNF398 promotes the pluripotency and the
epithelial character programmes in hPSCs. We decided to test the
function of ZNF398 in an orthogonal system, the induction of
pluripotency from somatic cells. Reprogramming from somatic
cells, such as fibroblasts, requires an early mesenchymal to epi-
thelial transition (MET) followed by the activation of endogenous
pluripotency factors23,47,48. We noticed that ZNF398 is expressed
in human fibroblasts (Supplementary Fig. 8a), raising the possi-
bility that ZNF398 promotes acquisition of epithelial character
and pluripotency from early stages of reprogramming. We
reprogrammed human fibroblasts by delivery of mRNAs encod-
ing for either OSKMNL23,47,48 (OCT4, SOX2, KLF4, MYC,
NANOG, LIN28A) or OSKM, in combination with siRNAs,
allowing to test the requirement of endogenous ZNF398 for
reprogramming (Fig. 8a). By day 6 of reprogramming, fibroblasts
transfected with control siRNAs formed clusters of epithelial cells,
indicative of MET. This effect was clearly reduced upon ZNF398
knockdown (Fig. 8b and Supplementary Fig. 8b). Around day
10 small colonies emerged and were stabilised over the following
6 days. Upon Control siRNA and OSKMNL transfection we
obtained 0.9% of reprogramming efficiency, which was reduced to
0.15% by ZNF398 knockdown. In the case of Control siRNA and
OSKM the efficiency was 0.5% and ZNF398 knockdown almost
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completely ablated formation of NANOG and OCT4-expressing
colonies (Fig. 8c, d).
Transcriptional analysis indicates a failure to activate a large
panel of pluripotency and epithelial markers upon ZNF398
knockdown (Fig. 8e and Supplementary Fig. 8c). Immunostaining
confirmed membrane localisation of E-cadherin only in
NANOG-positive reprogrammed colonies (Fig. 8f), accompanied
with loss of actin stress fibres, clearly visible in fibroblasts that
failed to reprogramme.
We also asked whether ZNF398 might be required for the
proliferation of fibroblasts, rather than for acquisition of pluripo-
tency and epithelial character. However, we could not observe a
reduction in cell number after 6 days of siZNF398 transfection and
levels of proliferation regulators were also unchanged (Supplemen-
tary Fig. 8d, e).
Thus, ZNF398 is required for efficient induction of epithelial
character and pluripotency from fibroblasts.
Discussion
TGF-beta signalling is critical for hPSC self-renewal5–7. The tran-
scription factor NANOG was first identified in murine ESCs for its
capacity to maintain pluripotency in the absence of exogenous
signals16. Such activity was also found conserved in hPSCs and
it was shown that TGF-beta directly induces NANOG expression
in hPSCs10,11. However, an unbiased and systematic analysis of
LIN28B
LEFTY1
ESRP1
qPCR
– +SB43
Empty ZNF398
LEFTY1
F
ol
d-
ch
an
ge
 to
 e
m
pt
y 
S
B
43
1
10
100
1000
KiPS
HES2
– +
a
SMAD3-ZNF398 co-bound targets
Empty ZNF398
M
ea
n-
no
rm
al
iz
ed
 T
P
M
NANOG
d
9.8e-09
0.86
0
1
2
3 RNA-seq - KiPS
Em
pty
ZN
F3
98
20
0
15
0
10
0
50
0
T
P
M
40
0
30
0
20
0
10
0
0
T
P
M
Em
pty
ZN
F3
98
15
0
10
0
50
0
T
P
M
Em
pty
ZN
F3
98
1
14
1
8
1
17
1
8
1
110
3.0 Kb
LIN28B
ZNF398 - H9
ZNF398 - BG01V
EP300
SMAD3
H3K27ac
M
ap
pe
d 
re
ad
s
M
ap
pe
d 
re
ad
s
1
13
1
15
1
8
1
56
1
87
2.5 Kb
LEFTY1
ZNF398 - H9
ZNF398 - BG01V
EP300
SMAD3
H3K27ac
1
20
1
17
1
16
1
17
1
119
5.0 Kb
ESRP1
ZNF398 - H9
ZNF398 - BG01V
EP300
SMAD3
H3K27ac
M
ap
pe
d 
re
ad
s
81 SMAD3 targets
Bound by ZNF398
Binding expected by chance
Not Bound by ZNF398
23
3.
49
e-
12
58
6.27
b c
e
1
1
EMPTY - Log2(TPM+1)
Z
N
F
39
8 
- 
Lo
g2
(T
P
M
+
1)
ZNF398 OE vs empty
RNA-seq - KiPS
%
 In
pu
t
ZN
F3
98
Mo
ck
%
 In
pu
t
ZN
F3
98
Mo
ck
%
 In
pu
t
ZN
F3
98
Mo
ck
6
4
2
0
0.9
0.6
0.3
0.0
3
2
1
0
BG01V
H9
BG01V
H9
BG01V
H9
ChIP-seq ChIP qPCR RNA-seq
0.0019
Fig. 7 ZNF398 boosts TGF-beta signal. a Left: Gene tracks of ZNF398 in two different hPSC lines (H9 and BG01V), EP300, SMAD3, and H3K27ac. Middle:
Barcharts of ChIP-qPCR for ZNF398 performed in BG01V (dark grey) and H9 (light grey) cell lines on LIN28B, ESRP1 and LEFTY1 loci. Enrichment is
expressed as a percentage of the DNA inputs. Bars indicate the mean of two biological replicates shown as dots. Right: RNA-seq of hPSCs (KiPS) stably
expressing an empty vector (Empty) or ZNF398. Bars indicate the mean ± SEM of independent experiments shown as dots (n= 4 and n= 2 in Empty and
ZNF398 overexpressing cells, respectively). Absolute expression is reported as TPM. Source data are provided as a Source Data file. b LEFTY1 levels
measured by qPCR of HES2 (light orange bars) and KiPS (dark orange bars) stably expressing an empty vector or ZNF398, untreated or treated with SB43
for 5 days. Bars indicate the mean ± SEM of independent experiments shown as dots (n= 4). Expression was normalised to the Empty SB43 samples and
shown on a logarithmic scale. Unpaired two-tailed Mann–Whitney U test. Source data are provided as a Source Data file. c Pie-chart representing the 81
SMAD3 direct targets UP-regulated by TGF-beta induction identified in Fig. 1c. In dark blue are shown the 23 SMAD3 targets that are also bound by
ZNF398. Such co-binding is significantly higher (p-value= 3.49e−12, Chi-squared test) than the one expected by chance, shown as the slice filled with
diagonal lines. d Mean-normalised expression levels of the 23 genes bound by ZNF398 and SMAD3. Shown data derived from RNA-seq analysis of KiPS
stably expressing an empty vector, NANOG (serving as a control) or ZNF398. For each gene, data was normalised to the mean-expression across the three
samples. Box plot indicates 25th, 50th and 75th percentile; whiskers indicate minimum and maximum. Unpaired two-tailed t-test. e Scatter plot showing
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TGF-beta functional mediators in hPSCs was still missing. For this
reason, we performed a transcriptome-level analysis of TGF-beta
targets followed by a gain-of-function screening to identify
uncharacterised pluripotency regulators.
Loss-of-function screenings have been performed in hPSCs,
whereby genes were inactivated by RNA interference or using the
CRISPR system30,31,49. Such studies identified some critical plur-
ipotency regulators, such as PRDM14 or BCOR. However, loss-of-
function approaches might fail to identify critical regulators
because of functional redundancy with other factors. For example,
a CRISPR screening in murine ESCs failed to identify the majority
of known pluripotency factors50, likely because the pluripotency
network is highly redundant and robust to inactivation of single
factors20,40. For this reason, we chose a gain-of-function screening
approach, whereby individual putative pluripotency regulators are
exogenously expressed in hPSCs and their capacity to maintain
pluripotency is tested. Such an approach allowed the identification
of several critical murine pluripotency regulators20.
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We identified a quartet of transcription factors, NANOG,
MYC, KLF7 and ZNF398, which individually promote hPSC self-
renewal. Interestingly, each of these four factors activates a spe-
cific subset of human pluripotency regulators3,19,29–34, indicating
that the human pluripotency network is flexible and can be
maintained under different configurations. Among them,
ZNF398 controls both pluripotency and epithelial genes down-
stream of TGF-beta (Fig. 8g).
Our analyses identified an extended set of functional human
pluripotency regulators beyond the core factors OCT4, SOX2 and
NANOG (Fig. 4b). It will be interesting to apply computational
modelling20 to reconstruct the network of interactions among
such factors in order to study how such a network reconfigures
itself after perturbations or during reprogramming.
Interestingly, only a fraction of human pluripotency regulators
are robustly expressed in murine ESCs (data from ref. 21). This
observation is in part attributable to differences in the develop-
mental stage, as conventional hPSCs are in a pluripotent stage
primed for differentiation, whereas murine ESCs are in a more
primitive, naïve state of pluripotency20,37.
However, naïve hPSCs have been recently obtained21–24 and
we observed that ZNF398 and KLF7 are robustly expressed in
hPSCs regardless of their pluripotency state. Moreover, forced
expression of both genes could not maintain pluripotency in
primed EpiSCs (Supplementary Fig. 4) and Klf7 expression in
murine ESCs had no effect40, indicating that the two factors are
human-specific pluripotency regulators.
It will be interesting to test whether the functions of TGF-beta
and its direct targets are conserved or divergent in naïve and
primed hPSCs.
Inhibitors of differentiation (ID) genes, such as ID1, block
neural differentiation in the developing mouse embryo51 and in
murine pluripotent stem cells52. ID1 is induced by BMP and by
TGF-beta52,53, also shown in our experiments. ID1 expression
had a mild yet reproducible effect on AP-positive colony for-
mation and maintenance of PRDM14 (Fig. 3a), and in the future
it will be interesting to study whether ID1 inhibits neural dif-
ferentiation also in hPSCs.
ZNF398 is a member of the Krüppel-associated box domain
zinc finger proteins (KZFPs), the largest family of transcriptional
regulators found in higher vertebrates. The majority of the 350
KZFPs identified in humans have been found to be associated
with repression of transposable elements54, playing key roles
during early embryogenesis. Interestingly, roughly one-third of
KZFPs, were found to be associated with gene promoters, as in
the case of ZNF398.
We are tempted to speculate that some members of such a
large family might have acquired new roles, beyond silencing of
transposable elements and in so doing, contributed to the evo-
lution of gene-regulatory networks.
ZNF398, also known as ZER6, has never been implicated in
regulation of pluripotency. Previous studies reported that
ZNF398 directly activates transcription44 and is regulated by
Oestrogen Receptor Alpha44,55. Two isoforms of ZNF398 have
been described44,55,56, called p71 and p52. The shorter isoform
(p52), lacks a N-terminal domain and promotes proliferation of
cancer cells by ubiquitination of p5356. In hPSCs the longer
isoform (p71) is predominant and has been used in all our
experiments. It will be interesting to test whether p52, which lacks
the N-terminal domain, regulates pluripotency in hPSCs.
Our results have also potential implications for reprogram-
ming: ZNF398 knockdown strongly reduced reprogramming
efficiency, indicating a critical role during establishment of
pluripotency.
In particular, we observed reduced morphological conversion
from mesenchymal to epithelial-like cells and reduced expression
of epithelial markers and pluripotency markers, further indicating
that ZNF398 promotes both pluripotency and epithelial character.
It will be interesting to see if ZNF398, or other members of
the extended set of human pluripotency regulators, can be
used to generate iPSCs at higher efficiency or to identify fully
reprogrammed cells.
Methods
Cell culture. hESCs (HES2, H9 and BG01V/hOG [BG01V, Gibco R7799105]) and
hiPSCs (KiPS, Keratinocytes induced Pluripotent Stem Cells) were cultured in
feeder-free on pre-coated plates with 0.5% growth factor-reduced Matrigel
(CORNING 356231) (vol/vol in PBS with MgCl2/CaCl2, Sigma-Aldrich D8662) in
E8 medium (made in-house according to Chen et al. 4) or in mTeSR (StemCell
Technologies 05850) at 37 °C, 5% CO2, 5% O2. Cells were passaged every 3–4 days
at a split ratio of 1:8 following dissociation with 0.5 mM EDTA (Invitrogen
AM99260G) in PBS without MgCl2/CaCl2 (Sigma-Aldrich D8662), pH8. The
human foreskin fibroblasts BJ (passage 12, ATCC, CRL-2522) were cultured in
DMEM/F12 (Sigma-Aldrich D6421) with 10% foetal bovine serum (FBS; Sigma-
Aldrich F7524) at 37 °C, 5% CO2, 21% O2. The H9 line (WA09) was obtained from
and used under authorisation from WiCell Research Institute. The KiPS line was
derived by reprogramming of human keratinocytes21 (Invitrogen) with Sendai
viruses encoding for OSKM and kindly provided by Austin Smith’s laboratory. The
HES2 line was derived from a female human embryo at the blastocyst stage, as
described in ref. 57 and kindly provided by Nicola Elvassore’s laboratory.
EpiSC lines (GOF1827 and OEC238, kindly provided by Hans R. Schöler’s
laboratory and Austin Smith’s laboratory, respectively) were cultured on serum-
coated (GMEM [Sigma-Aldrich G5154] with 10% FBS) plates in serum-free media
N2B27 (DMEM/F12 [Gibco 11320-074], and Neurobasal in 1:1 ratio [Gibco 21103-
049], with 1:200 N2 Supplement [Gibco 17502-048], and 1:100 B27 Supplement
[Gibco 17504-044], 2 mM L-glutamine [Gibco 25030-024], 0.1 mM 2-
mercaptoethanol [Sigma-Aldrich M3148]) supplemented with FGF2 (12 ng/ml,
QKINE Qk002, recombinant zebrafish FGF2) and Activin A (20 ng/ml, QKINE
Qk001), and passed as small cell clumps every 2 days.
Fig. 8 ZNF398 is required for somatic cells reprogramming. a Experimental strategy for reprogramming by delivery of OSKM (OCT4, SOX2, KLF4, MYC)
mRNAs in combination with siRNAs in order to test the requirement of ZNF398 for reprogramming. Scale bars 50 µm. See also “Methods” section for
details. b Cell morphology during OSKM reprogramming. Representative images of two independent experiments are shown. See also Supplementary
Fig. 8b. c Number of iPSC colonies obtained from 100 cells seeded at day 14 in OSKMNL reprogramming and at day 16 in OSKM reprogramming under the
indicated conditions. Bars indicate the mean ± SEM of independent experiments. p-values: unpaired two-tailed Mann–Whitney U test. OSKMNL
reprogramming: dots indicate biological replicates (n= 23, 24 and 23 replicates for no siRNA, siCONTROL and siZNF398, respectively) from four
independent experiments shown in different shades of colours. OSKM reprogramming: dots indicate biological replicates (n= 15 for replicates scored
based on morphology or NANOG signal, n= 8 for replicates scored based on OCT4 signal) from two independent experiments shown in different shades
of colours. Source data are provided as a Source Data file. d Immunostaining for OCT4 and NANOG of fibroblasts transfected with OSKM mRNAs and
siCONTROL or siZNF398 at day 16. Representative images of two independent experiments are shown. Scale bars 150 µm. e Gene expression analysis by
qPCR of hiPSCs (KiPS) (light grey) and fibroblasts (dark grey) serving as controls, and fibroblasts transfected with OSKMNL mRNAs and siCONTROL (light
orange) or siZNF398 (dark orange) at day 6 and day 14. Bars indicate the mean of two independent experiments shown as dots. Expression was
normalised to the mean of KiPS samples. See also Supplementary Fig. 8a, c. Source data are provided as a Source Data file. f Immunostaining for NANOG
and E-Cadherin followed by Phalloidin staining of fibroblasts transfected with OSKM mRNAs and siCONTROL or siZNF398 at day 16. Representative
images of two independent experiments are shown. Scale bars 150 µm. g Diagram representing the transcription factors induced by TGF-beta, among
which ZNF398 is crucial for the maintenance of pluripotency and the epithelial character of hPSCs.
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MCF10A and MCF10neoT were cultured in DMEM/F12 with 5% horse serum
(HS) (ThermoFisher 16050-122), 10 µg/ml insulin (Sigma-Aldrich I9278), 100 ng/
ml cholera toxin (Sigma-Aldrich C8052), 20 ng/ml hEGF (Peprotech AF100-15),
500 ng/ml hydrocortisone (Sigma-Aldrich H0396) and 2 mM L-glutamine. RPE-1,
MCF10CA1a, A549 and MDA-MB-231 were cultured in DMEM/F12 with 10%
FBS and 2mM L-glutamine. HEK293T and HaCaT were cultured in DMEM
(Gibco 41965-039) with 10% FBS and 2mM L-glutamine. WI-38 cells were
cultured in MEM (Gibco 32360-026) with 10% FBS and 5% O2. HepG2 were
cultured in MEM with 10% FBS, 1.5% MEM non‐essential amino acids (NEAA,
Invitrogen 1140‐036) and 4 mM L-glutamine. MCF10A, MCF10AneoT, RPE-1,
MCF10CA1a, A549, MDA-MB-231, HEK293T, WI-38 and HepG2 were kindly
provided by Sirio Dupont’s laboratory. HaCaT cells were kindly provided by
Stefano Piccolo’s laboratory.
All cell lines were mycoplasma-negative (Mycoalert, Lonza).
Treatment with inhibitors and cytokines. Treatments were performed either
under feeder-free conditions or on feeders (MEF, Murine Embryonic Fibroblasts
mitotically inactivated, DR4 ATCC). For the validation experiments of Fig. 2a in
feeder-free, KiPS were plated on plastic coated with 0.5% Matrigel. The next day,
cells were treated with DMSO (Sigma-Aldrich D2650) or 10 μM SB43 (Axon
Medchem 1661) overnight. The morning after, TGF-beta signalling was re-induced
by changing medium with mTeSR1 for 1 h or for 4 h. For the validation experi-
ments on feeders, KiPS were plated on MEF with KSR medium [DMEM/F12, with
20% KnockOut Serum Replacement (KSR, Gibco 108828028), 2 mM L-glutamine,
1% NEAA and 0.1 mM 2-mercaptoethanol] and with 10 ng/ml FGF2. The next day,
cells were treated with DMSO or with 10 μM SB43 overnight. The morning after,
cells were treated with 2 ng/ml of TGFB1 (Peprotech 100-21) or with 25 ng/ml of
Activin A.
For the BMP induction experiment in Supplementary Fig. 6c, KiPS were plated
under feeder-free conditions. The next day, cells were treated with DMSO or
0.1 μM LDN 193189 (LDN, Axon Medchem 1509) overnight. The morning after,
BMP signalling was re-induced by changing medium with E8 with 100 ng/ml of
BMP4 (Peprotech 120-05ET) for 1 h.
Generation of hPSCs stably expressing genes of interest. Stable transgenic
hPSCs expressing candidates were generated by transfecting cells with PB trans-
poson plasmids with PB transposase expression vector pBase. In order to generate
the PB plasmids, the candidates (NANOG, ZNF398, KLF7, MYC, ETS2, OTX2,
ID1, BCOR and PRDM14) were amplified from cDNA and cloned into a
pENTR2B donor vector. Then, the transgenes were Gateway cloned into the same
destination vector containing PB-CAG-DEST-bghpA and pGK-Hygro selection
cassette.
For DNA transfection, 250,000 hPSCs were dissociated as single cells with
TrypLE (Gibco 12563-029) and were co-transfected with PB constructs (550 ng)
and pBase plasmid (550 ng) using FuGENE HD Transfection (Promega E2311),
following the protocol for reverse transfection. For one well of a 12-well plate, we
used 3.9 μl of transfection reagent, 1 μg of plasmid DNA, and 250,000 cells in 1 ml
of E8 medium with 10 µM Y27632 (ROCKi, Rho-associated kinase (ROCK)
inhibitor, Axon Medchem 1683). The medium was changed after overnight
incubation and Hygromycin B (200 μg/ml; Invitrogen 10687010) was added after
48 h. For the overexpression experiments, hPSCs stably expressing an empty vector
or the candidates were plated. The next day, cells were treated with DMSO or
10 µM SB43 for 5 days and then analysed as indicated in Supplementary Fig. 2a.
Murine EpiSCs experiments. For generation of stable transgenic lines over-
expressing candidate genes, EpiSCs were reverse-transfected with 3 µl of Lipo-
fectamine 2000 (Invitrogen 11668-019) using 500 ng of PB transposon plasmid
harbouring the indicated factor and 500 ng of transposase in 200 µl of Opti-MEM
(Gibco 51985-026). 1.2 × 105 cells in 800 µl of N2B27 with FGF2 (12 ng/ml) and
Activin A (20 ng/ml) and 10 µM ROCKi were added to the transfection mix and
plated in serum-coated 12-well plates. The next day the medium was changed and
Hygromycin B selection was applied for 5 days. To test the effect of TGF-beta
inhibitors, 1/20 of a confluent well was plated on serum-coated 12-well in N2B27
medium with FGF2 and Activin A. The next day, the medium was changed to
N2B27 with FGF2 and 1 µM SB43 or FGF2 and 1 µM A83 (Axon Medchem 1421).
After 48 h, cells were harvested for expression analysis.
siRNA and DNA transfection in HEK293T and HaCaT cell lines. Cells were
plated at 20% confluence on a 24-well plate the day before transfection. For
transfection with siRNAs, each individual well was transfected with Lipofectamine
RNAiMAX reagent (ThermoFisher 13778075) following the manufacturer protocol
(0.2 µl of 100 µM siRNA with 1 µl of transfection reagent per well). For transfection
with DNA, each individual well was transfected with a mix of: 2.25 µl of poly-
ethylenimine (PEI, Polysciences 23966), 750 ng DNA in 100 µl Opti-MEM. In cases
of treatment with TGF-beta, cells were starved in medium without serum (+10 µM
SB43, for SB43 samples only), 24 h after transfection. After overnight incubation,
the medium was replaced with DMEM without serum and with 10 µM SB43 or 5
ng/ml TGFB1 for 6 h.
siRNA transfection in hPSCs. For siRNA transfection, hPSCs were plated on
Matrigel-coated 24-well plate as clusters (2500–5000 clusters for one well of a 24-
well plate) in E8 medium with 10 µM ROCKi. After 4 h, siRNAs were transfected at
a final concentration of 20 nM using StemfectTM RNA Transfection Kit (STEM-
GENT 00-0069), following the protocol for forward transfection.
For a 24-well plate (2 cm2), we used 0.52 µl of transfection reagent, 2 µl of
10 µM siRNA solution and 25 µl of transfection buffer. After waiting 20 min, we
mixed the transfection mix with 1 ml of E8 medium. The medium was changed
after overnight incubation. See Supplementary Table 1 for sequences of the
siRNAs used.
EBs differentiation assay. KiPS stably expressing an empty vector or ZNF398
were detached as clumps with EDTA and plated on ultra low attachment surface
plates (CORNING 3473) in E8 medium with 10 µM ROCKi. After 2 days, E8
medium was substituted with DMEM, 20% FBS, 2 mM L-glutamine, 1% NEAA and
0.1 mM 2-mercaptoethanol. Medium was changed every 2 days.
Reprogramming. All reprogramming experiments were performed in micro-
fluidics in hypoxia conditions (37 °C, 5% CO2, 5% O2)48. The protocol for
reprogramming experiments was optimised to transfect siRNA in order to test the
requirement of ZNF398 for reprogramming.
Briefly, microfluidic channels were coated with 25 μg/ml Vitronectin
(ThermoFisher, A14700) for 1 h at room temperature (RT). In the case of
OSKMNL reprogramming, fibroblasts were seeded at day 0 at 30 cells/mm2 in
DMEM/10% FBS. On day 1, 9 h before the first mRNAs transfection, we applied E6
medium (made in-house according to Chen et al. 4) including 100 ng/ml FGF2,
5 µM ROCKi, 0.1 μM LSD1i (RN-1, EMD Millipore 489479) and 20% KSR (Gibco,
10828028). The transfection mix was prepared according to the StemMACS™
mRNA Transfection Kit (Miltenyi Biotec, 130-104-463) and Stemgent StemRNA-
NM Reprogramming Kit (Reprocell, 00-0076) (OSKMNL not-modified RNA
(NM-RNA) and EKB NM-RNA (used to reduce interferon response) and we
prepared the RNA mix according to the manufacturer’s instructions.
In the case of OSKM reprogramming, individual modified mRNAs (OCT4,
SOX2, KLF4 and MYC) were made in-house by in vitro transcription using mRNA
synthesis with HiScribe™ T7 ARCA mRNA Kit (NEB E2060S) according to the
manufacturer’s instructions. On day 0, fibroblasts were seeded at 15 cells/mm2 in
DMEM/10% FBS. On day 1, 9 h before the first mRNAs transfection, we applied E6
medium including 100 ng/ml FGF2, 5 µM ROCKi, 0.1 μM LSD1i, 1% KSR and 200
ng/ml B18R (Invitrogen 34-8185-81). The B18R protein was added to the medium
to reduce the interferon response. The transfection mix was prepared according to
the StemMACS™ mRNA Transfection Kit and using OSKM mRNAs made in-
house and NM-microRNAs (Stemgent StemRNA-NM Reprogramming Kit). Cells
were transfected daily at 6 p.m. and fresh medium was given daily at 9 a.m. siRNAs
were transfected at a final concentration of 20 nM at day 1, day 3 and day 5 (see
Supplementary Table 1 for sequences of the siRNAs used) together with mRNAs.
The dose of mRNAs transfected was gradually increased according to cell
proliferation rate and transfection-induced cell mortality48.
Immunofluorescence and stainings. Immunofluorescence analysis was per-
formed on 1% Matrigel-coated glass coverslip in wells or in situ in microfluidic
channels with the same protocol. Cells were fixed in 4% formaldehyde (Sigma-
Aldrich 78775) in PBS for 10 min at RT, washed in PBS, permeabilized for 1 h in
PBS+ 0.3% Triton X-100 (PBST) at RT, and blocked in PBST+ 5% of HS
(ThermoFisher 16050-122) for 5 h at RT. Cells were incubated overnight at 4 °C
with primary antibodies (see Supplementary Table 2) in PBST+ 3% of HS. After
washing with PBS, cells were incubated with secondary antibodies (Alexa, Life
Technologies) (Supplementary Table 2) for 45 min at RT. Nuclei were stained with
either DAPI (4′,6-diamidino-2-phenylindole, Sigma-Aldrich F6057) or Hoechst
33342 (ThermoFisher 62249). In the case of Phalloidin staining (see Fig. 8f), Alexa
Fluor 488 Phalloidin and Hoechst were added with secondary antibodies. Images
were acquired with a Zeiss LSN700 or a Leica SP5 confocal microscope using ZEN
2012 or Leica TCS SP5 LAS AF (v2.7.3.9723) software, respectively.
For alkaline phosphatase staining, cells were fixed with a
citrate–acetone–formaldehyde solution and stained using an alkaline phosphatase
detection kit (Sigma-Aldrich 86R-1KT). Plates were scanned using an Epson
scanner and scored manually.
Image analysis. Fiji 1.0 (ImageJ2)58 was used for image analysis. Fluorescence
intensity across hPSCs (Supplementary Fig. 6b) was measured using the Plot
Profile function. For each condition, 48 cells from six randomly selected fields were
analysed. Fluorescence intensity (Fig. 4a, Supplementary Fig. 3c) was quantified
using Cell Profiler software (v3.1.8).
Western blotting. To monitor endogenous protein levels, cells were detached,
medium removed and frozen at −80 °C prior to processing. Pellets were then thawed
and resuspended in 10ml/cm2 HPO buffer (50mM Hepes pH 7.5, 100mM NaCl,
50mM KCl, 1% triton X-100, 0.5% NP-40, 5% glycerol, 2 mM MgCl2) freshly sup-
plemented with 1mM DTT, protease inhibitors (Roche 39802300) and phosphatase
inhibitors (Sigma-Aldrich P5726). Western blotting was performed as in ref. 59.
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Western blotting was acquired with LAS400 ImageQuant 1.2. Antibodies are detailed
in Supplementary Table 2. Uncropped gels are provided in the Source data file.
Quantitative PCR. Total RNA was isolated using Total RNA Purification Kit
(Norgen Biotek 37500), and complementary DNA (cDNA) was made from 500 ng
using M-MLV reverse transcriptase (Invitrogen 28025-013) and dN6 primers. For
real-time PCR SYBR Green Master mix (Bioline BIO-94020) was used. Primers are
detailed in Supplementary Table 3. Three technical replicates were carried out for
all quantitative PCR. GAPDH was used as endogenous control to normalise
expression. qPCR data were acquired with QuantStudio™ 6&7 Flex Software 1.0.
RNA sequencing. For induction experiments (Fig. 1d), poly(A) mRNA was pur-
ified from total RNA using the Dynabeads mRNA direct kit (ThermoFisher,
61011). Quantity and quality of the starting mRNA were checked by Qubit and
Agilent Bioanalyzer 2100 RNA pico chip. The template library was prepared using
the Ion Total RNA-Seq Kit v2 (ThermoFisher, 4475936). Quantity and size dis-
tribution of the library were analysed using the Agilent Bioanalyzer 2100 DNA HS
chip. Emulsion PCR using 10 ml of 100 pM library was performed using a One-
Touch 2 instrument (ThermoFisher, 4474778) with an Ion PI Template OT2 200
kit following the manufacturer’s instructions (ThermoFisher, 4488318). The
enrichment of the template library was achieved using the Ion OneTouch ES
enrichment system (ThermoFisher). Ion Proton sequencer and IPv2 chip were
prepared according to the manufacturer’s recommendations. Raw reads were
aligned in two steps: first reads were aligned on genome build GRCh37.p13 with
STAR (v2.4), reads that were not aligned in this step were realigned with bowtie2
(v2.2.4). Raw counts over the ensembl annotation release 75 were obtained with
htseq-count (v0.6.0). Normalisation and differential analysis were carried out using
edgeR package (v3.4.2)60 and R (version 3.5.2, R Core Team (2018). R: A language
and environment for statistical computing. R Foundation for Statistical Comput-
ing, Vienna, Austria. https://www.R-project.org/). EdgeR fits genewise negative
binomial generalised linear models and conducts likelihood ratio test. Raw counts
were normalised to obtain counts per million-mapped reads (CPM) and reads per
kilobase per million mapped reads (RPKM). Only genes with a CPM >1 in at least
two samples were retained for differential analysis. Differences between batches
were adjusted using an additive model. Genes were considered significantly
upregulated with a p-value ≤ 0.05 and a fold-change ≥1.5.
For overexpression experiments (Figs. 4b, c and 5a), ~2 μg of total RNA were
subjected to poly(A) selection, and libraries were prepared using the TruSeq RNA
Sample Prep Kit (Illumina) following the manufacturer’s instructions. Sequencing
was performed on the Illumina NextSeq 500 platform. Reads were mapped to the
Homo sapiens hg19 reference assembly using TopHat (v2.1.1), and gene counts
were computed using htseq-count (v0.6.1p1)61. Differential expression analysis was
performed using DESeq v262. Genes with abs (Log2 fold-change) ≥ 1 and p-value <
0.01 were considered significant and defined as differentially expressed
(differentially expressed genes (DEG)).
GO terms for biological processes analysis of DEGs was performed using
Database for Annotation, Visualisation and Integrated Discovery (DAVID)
database63 (https://david.ncifcrf.gov). Boxplots and Scatterplots were made using
TPM values exploiting ggpubr R package (v. 0.2), ggboxplot and ggscatter
functions, respectively. Heatmaps were produced using TPM values with the
pheatmap function from pheatmap R package (v.1.0.12, distance= ‘correlation’,
scale= ‘row’) on selected markers. Volcano plots were computed with Log2 fold-
change and −Log10 p-value using ggscatter function from ggpubr R package
(v. 0.2).
Microarray analysis. Public gene expression data of hESCs treated with SB43 were
downloaded from ArrayExpress (E-MEXP-1741). Differentially expressed genes
were identified applying limma (v3.18.13)64 on the RMA normalised gene
expression matrix. Limma fits a linear model for each gene and calculates mod-
erated t-statistics and p-values with an empirical Bayes moderation approach.
To identify genes associated with TGF-beta inhibition, we compared the
expression levels of hESCs treated with SB43 or control cells and selected those
probe sets with a fold change lower than or equal to −2 and an FDR lower than or
equal to 0.05. Microarray analyses were performed in R (version 3.5.2).
ChIP sequencing and ChIP quantitative PCR. ChIP-seq data of SMAD3 in BG03
embryonic stem cells were retrieved from GEO (GSE21614). We analysed the
chromatin IP against Smad3 (GSM539548) and whole cell extract (WCE) in the
same cell line (GSM539552). Raw reads were aligned using Bowtie (version 0.12.7)65;
to build version hg19 of the human genome retaining only uniquely mapped reads.
Redundant reads were removed using SAMtools (v0.1.18). MACS2 (v2.0.10)66 was
used to call peaks for SMAD3 using WCE ChIP-seq as control sample and setting
the bandwidth equal to the estimated sonication fragment size (131 bp) and the
p-value cutoff at 0.01. Only peaks with a pileup height >5 were kept for further
analysis. Each peak was assigned to the nearest TSS in a window of 100 kb centred
on the peak, considering only protein-coding genes in GENCODE v16 annotation.
For identification of ZNF398 targets, we performed chromatin
immunoprecipitation in two independent hESC lines (H9 and BG01V)67,68. Cells
(~3 × 107) co-transfected with Avi-Tag-ZNF398 and E. coli birA protein were
crosslinked in 1% formaldehyde for 10 min at room temperature. Crosslinking was
quenched by addition of 0.125 M final glycine. Cells were then harvested by
scraping in ice-cold PBS and collected by centrifugation. The cell pellet was then
resuspended in 1 ml ice-cold ChIP buffer [20 mM Tris–HCl pH 8.0; 0.1% SDS; 1%
Triton X-100; 2 mM EDTA; 150 mM NaCl], supplemented with protease inhibitor
cocktail (Sigma-Aldrich, P8340) and incubated on ice for 10 min. The cell
suspension was then sonicated with a Diagenode Bioruptor Twin (settings: 30 s
ON, 30 s OFF, high power) for 10 cycles. The sample was then kept on ice for 10
min and sonication was repeated for additional 10 cycles. The lysate was then
centrifuged at 17,000×g for 10 min (4 °C) to remove membranes and the
supernatant was transferred to a new tube. 50 μl of Dynabeads MyOne Streptavidin
T1 (Thermo Fisher, 65601), pre-equilibrated for 30 min in PBS supplemented with
1% BSA, were then added to the sample. The sample-beads suspension was then
rotated at 4 °C for 3 h. Following incubation, supernatant was discarded and beads
were washed (in 1 ml volume) twice with Wash buffer 1 [2% SDS], twice with
Wash buffer 2 [50 mM HEPES pH 7.5; 500 mM NaCl; 1 mM EDTA; 1% Triton X-
100; 0.1% sodium deoxycholate], once with Wash buffer 3 [10 mM Tris–HCl pH
8.0; 250 mM LiCl; 1 mM EDTA; 0.5% NP-40; 0.5% sodium deoxycholate] and once
in TE buffer. Beads were then resuspended in 200 μl Elution buffer [50 mM
Tris–HCl pH 8.0; 10 mM EDTA; 1% SDS] and incubated at 56 °C for 16 h. After
incubation, beads were discarded and five volumes (1 ml) of buffer PB were added
to the supernatant, prior to DNA purification on QIAquick PCR Purification kit’s
columns (QIAGEN, 28104), according to the manufacturer instructions. The ChIP-
seq library was prepared with ~5 ng of immunoprecipitated DNA as input for the
NEBNext® ChIP-Seq Library Prep kit, following the manufacturer’s instructions.
Sequencing was performed on the Illumina NextSeq 500 platform. Reads were
mapped to the Homo sapiens hg19 reference assembly using Bowtie (v1.2.2)65,
keeping only uniquely mapped reads. Reads (75 bp) were bioinformatically
extended to the average insert size (150 bp), and identical reads (reads starting and
ending at the same positions) were collapsed. Peak calling was performed using
MACS v2.1.166, selecting only peaks with q-value < 0.05. A non-redundant set of
common peaks between the two ZNF398 ChIP-seq replicates was generated using
the intersectBed utility from BEDTools (v2.26.0)69. For motif discovery, peaks were
resized to ±200 bp surrounding their center and motif discovery was performed
using MEME (v4.10.1)70. For correlation analyses and comparison of ZNF398
genome occupancy with known factors/histone modifications, data was collected
from the GEO database for the following datasets: GSE54471 (H3K27ac and
H3K4me1), GSE76084 (H3K27me3, H3K36me3, H3K4me3, H3K9ac, SOX2),
GSE118325 (H3K9me3), GSE73725 (NANOG). Data for POU5F1 and EP300 was
instead obtained from the ENCODE database (https://www.encodeproject.org/).
All samples were analysed as stated above. Spearman correlations between genomic
occupancy profiles were computed using the multiBamSummary and
plotCorrelation utilities from deepTools v2.2.471. Heatmaps of peak densities
around ZNF398 peaks centers were generated using in-house developed scripts.
For SMAD3 and SMAD2 ChIP-qPCR, hESC lines (H9 and BG01V) were
treated with 25 ng/ml Activin A to activate the TGF-β pathway for 1 h and cross-
linked by addition of formaldehyde to 1% for 10 min at RT, quenched with 0.125 M
glycine for 5 min at RT, and then washed twice with cold PBS. The cells were
resuspended in Isotonic buffer supplemented with 1% NP-40 to isolate nuclei. The
pellets were then resuspended in ChIP buffer (20 mM Tris–HCl pH 8.0, 10 mM
EDTA, 1% SDS). Extracts were sonicated using the BioruptorH Twin (Diagenode)
for two runs of 10 cycles (30 s on, 30 s off) and diluted with ChIP dilution buffer
(20 mM Tris–HCl pH 8.0, 150 mM NaCl, 2 mM EDTA, 1% Triton) before the
immunoprecipitation step with 2 μg of antibody overnight at 4 °C on a rotator.
Subsequently immunoprecipitated complexes were washed six times with RIPA
buffer (50 mM HEPES–KOH pH 7.6, 500 mM LiCl, 1 mM EDTA, 1% NP-40, 0.7%
Na-Deoxycholate) and eluted in SDS Elution buffer. De-crosslinked DNA was
purified using QiaQuick PCR Purification Kit (Quiagen) according to the
manufacturer’s instruction.
The ChIP-seq data were validated by ChIP–qPCR, using two independent
biological replicates for each hESC lines (H9 and BG01V). The data represent
qPCR measurements of the immunoprecipitated DNA performed using SYBR
GreenER kit (Invitrogen) and were normalised to those obtained with a non-
immune serum (IgG). The data are expressed as a percentage of the DNA inputs.
Primers for ChIP–qPCR are detailed in Supplementary Table 4.
Protein coimmunoprecipitation. To detect the protein interaction, nuclei were
isolated from H9 cells expressing Avi-Tag-ZNF398 which were induced with 25 ng/
ml Activin A for 1 h. Cells were lysed with Isotonic buffer supplemented with 1%
NP-40. The nuclei pellets were resuspended in IP buffer (50 mM Tris–HCl pH 8.0,
100 mM NaCl, 200 mM sucrose, 0.5 mM MgCl2, 5 mM CaCl2, 5 μM ZnCl2) and
were treated with micrococcal nuclease at 30 °C for 10 min. Nuclear proteins were
incubated with 2 μg of indicated antibodies (Supplementary Table 2) overnight at
4 °C. The immunoprecipitated complexes were incubated with Protein G magnetic
beads (Invitrogen) for 2 h at 4 °C and then were washed three times with IP buffer
plus 0.5% NP-40. The precipitated proteins were eluted by incubating with 0.5 M
NaCl TE buffer and were further analysed by western blotting.
Statistics and reproducibility. For each dataset, sample size n refers to the
number of independent experiments or biological replicates, shown as dots, as
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stated in the figure legends. A Gaussian distribution was not assumed and p-values
were calculated using the non-parametric unpaired two-tailed Mann-Whitney U
test with the exception of induction experiments (Fig. 2a, b) for which we used the
unpaired two-tailed t-test. p-values were not calculated for datasets with n < 3.
p-values are reported in the plots or figure legends. R software (v3.5.2) was used
for statistical analysis.
All error bars indicate the standard error of the mean (SEM). All key experiments
were repeated between two and five times independently, as indicated. Experiments of
candidate’s functional validation were repeated using three different hPSC lines. All
qPCR experiments were performed with three technical replicates.
Reporting summary. Further information on research design is available in
the Nature Research Reporting Summary linked to this article.
Data availability
RNA-seq and ChIP-seq data for this study have been deposited in the Gene Expression
Omnibus (GEO) database under the accession code: GSE133630 . For the identification
of TGF-beta transcriptional targets, we used available SMAD3 ChIP-seq data from15
(Accession no. GSE21621), microarray data from13 (Accession no. E-MEXP-1741) and
RNA-seq data of H9 from72, (Accession no. GSE24447, see Supplementary Fig. 1e). For
correlation analyses and comparison of ZNF398 genome occupancy with known factors/
histone modifications, data was collected from the GEO database for the following
datasets: GSE54471 (H3K27ac and H3K4me1), GSE76084 (H3K27me3, H3K36me3,
H3K4me3, H3K9ac, SOX2), GSE118325 (H3K9me3), GSE73725 (NANOG). Data for
POU5F1 and EP300 was instead obtained from the ENCODE database (https://www.
encodeproject.org/). All plasmids, materials and data supporting the findings of this
study are available from corresponding authors upon reasonable request. The source data
underlying Figs. 1b, 2a, b, 3a, c, 4a, 5d, e, 6c, 7a, b, 8c, e and Supplementary Figs. 1b, f, g,
2d, 3a, c, d, 4a, b, 5a–c, 6b, 7a-d, 8a, c–e are provided as a Source Data file.
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